Loading...
Market
Asahi Kasei completes acquisition of Calliditas by end of 2024?
5
Asahi Kasei•Swedish•Calliditas Therapeutics•American Depositary Share•ADS•Calliditas•Tarpeyo•SofinnovaVC•Amolyt Pharma•CLI LimFlow
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from Asahi Kasei or Calliditas Therapeutics
Story
Asahi Kasei to Acquire Calliditas Therapeutics for $1.1 Billion in SEK 416 per ADS Deal
May 28, 2024, 09:19 AM
Japanese conglomerate Asahi Kasei has announced its intention to acquire Swedish drugmaker Calliditas Therapeutics for approximately $1.1 billion. The deal, which includes an offer of SEK 416 or about USD $39.37 in cash per American Depositary Share (ADS), aims to bolster Asahi Kasei's pharmaceutical business. Calliditas, known for its IgA nephropathy therapy Tarpeyo, will be acquired for $1.05 billion in cash. The acquisition price is also noted as SEK 208 per share or 1.2 billion dollars. This acquisition marks the third successful exit for SofinnovaVC in the last six months, following the exits of Amolyt Pharma and CLI LimFlow.
View original story
Similar markets
Significant growth in revenue • 25%
Moderate growth in revenue • 25%
Revenue remains stable • 25%
Revenue declines • 25%
Highly successful integration • 25%
Moderately successful integration • 25%
Integration with issues • 25%
Integration fails • 25%
Bristol Myers Squibb • 25%
Gilead Sciences • 25%
Novartis • 25%
Other • 25%
Stock price up more than 10% • 25%
Stock price up 5-10% • 25%
Stock price unchanged or down • 25%
Stock price down more than 5% • 25%
Yes • 50%
No • 50%
